Cargando…

Emerging Computational Methods for the Rational Discovery of Allosteric Drugs

[Image: see text] Allosteric drug development holds promise for delivering medicines that are more selective and less toxic than those that target orthosteric sites. To date, the discovery of allosteric binding sites and lead compounds has been mostly serendipitous, achieved through high-throughput...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jeffrey R., Lee, Christopher T., Durrant, Jacob D., Malmstrom, Robert D., Feher, Victoria A., Amaro, Rommie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901368/
https://www.ncbi.nlm.nih.gov/pubmed/27074285
http://dx.doi.org/10.1021/acs.chemrev.5b00631
_version_ 1782436794290143232
author Wagner, Jeffrey R.
Lee, Christopher T.
Durrant, Jacob D.
Malmstrom, Robert D.
Feher, Victoria A.
Amaro, Rommie E.
author_facet Wagner, Jeffrey R.
Lee, Christopher T.
Durrant, Jacob D.
Malmstrom, Robert D.
Feher, Victoria A.
Amaro, Rommie E.
author_sort Wagner, Jeffrey R.
collection PubMed
description [Image: see text] Allosteric drug development holds promise for delivering medicines that are more selective and less toxic than those that target orthosteric sites. To date, the discovery of allosteric binding sites and lead compounds has been mostly serendipitous, achieved through high-throughput screening. Over the past decade, structural data has become more readily available for larger protein systems and more membrane protein classes (e.g., GPCRs and ion channels), which are common allosteric drug targets. In parallel, improved simulation methods now provide better atomistic understanding of the protein dynamics and cooperative motions that are critical to allosteric mechanisms. As a result of these advances, the field of predictive allosteric drug development is now on the cusp of a new era of rational structure-based computational methods. Here, we review algorithms that predict allosteric sites based on sequence data and molecular dynamics simulations, describe tools that assess the druggability of these pockets, and discuss how Markov state models and topology analyses provide insight into the relationship between protein dynamics and allosteric drug binding. In each section, we first provide an overview of the various method classes before describing relevant algorithms and software packages.
format Online
Article
Text
id pubmed-4901368
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-49013682016-06-16 Emerging Computational Methods for the Rational Discovery of Allosteric Drugs Wagner, Jeffrey R. Lee, Christopher T. Durrant, Jacob D. Malmstrom, Robert D. Feher, Victoria A. Amaro, Rommie E. Chem Rev [Image: see text] Allosteric drug development holds promise for delivering medicines that are more selective and less toxic than those that target orthosteric sites. To date, the discovery of allosteric binding sites and lead compounds has been mostly serendipitous, achieved through high-throughput screening. Over the past decade, structural data has become more readily available for larger protein systems and more membrane protein classes (e.g., GPCRs and ion channels), which are common allosteric drug targets. In parallel, improved simulation methods now provide better atomistic understanding of the protein dynamics and cooperative motions that are critical to allosteric mechanisms. As a result of these advances, the field of predictive allosteric drug development is now on the cusp of a new era of rational structure-based computational methods. Here, we review algorithms that predict allosteric sites based on sequence data and molecular dynamics simulations, describe tools that assess the druggability of these pockets, and discuss how Markov state models and topology analyses provide insight into the relationship between protein dynamics and allosteric drug binding. In each section, we first provide an overview of the various method classes before describing relevant algorithms and software packages. American Chemical Society 2016-04-13 2016-06-08 /pmc/articles/PMC4901368/ /pubmed/27074285 http://dx.doi.org/10.1021/acs.chemrev.5b00631 Text en Copyright © 2016 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Wagner, Jeffrey R.
Lee, Christopher T.
Durrant, Jacob D.
Malmstrom, Robert D.
Feher, Victoria A.
Amaro, Rommie E.
Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title_full Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title_fullStr Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title_full_unstemmed Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title_short Emerging Computational Methods for the Rational Discovery of Allosteric Drugs
title_sort emerging computational methods for the rational discovery of allosteric drugs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901368/
https://www.ncbi.nlm.nih.gov/pubmed/27074285
http://dx.doi.org/10.1021/acs.chemrev.5b00631
work_keys_str_mv AT wagnerjeffreyr emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs
AT leechristophert emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs
AT durrantjacobd emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs
AT malmstromrobertd emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs
AT fehervictoriaa emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs
AT amarorommiee emergingcomputationalmethodsfortherationaldiscoveryofallostericdrugs